EGFR and glioblastoma: INTELLANCE-1, the phase III randomized, double-blind, placebo-controlled study of Depatux-M in combination with radiotherapy/temozolomide versus radiotherapy/temozolomide alone in EGFR-amplified newly-diagnosed glioblastomas unfortunately found no survival benefit at an interim analysis; the study was stopped for futility [108].